All In MedTech

FDA Clearance Tracker · P220026-S014

Symplicity Spyral™ Renal Denervation System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 10, 2026

Approved

Time to decision

225 days

Received Jan 28, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P220026-S014
Device name
Symplicity Spyral™ Renal Denervation System
Applicant location
Santa Rosa, CA
Received
Jan 28, 2026
Decided
Sep 10, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P220026

Device type

Device class
Class III

Every decision under product code QYI

FDA's approval statement

As written in FDA's record.

inclusion of data from post-approval studies in labeling

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.